These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 32577668)

  • 41. Treatment of COVID-19 pneumonia with glucocorticoids (CORTIVID): a structured summary of a study protocol for a randomised controlled trial.
    Les Bujanda I; Loureiro-Amigo J; Bastons FC; Guerra IE; Sánchez JA; Murgadella-Sancho A; Rey RG; López JL; Álvarez JS
    Trials; 2021 Jan; 22(1):43. PubMed ID: 33430891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Robust extraction of covariate information to improve estimation efficiency in randomized trials.
    Moore KL; Neugebauer R; Valappil T; Laan MJ
    Stat Med; 2011 Aug; 30(19):2389-408. PubMed ID: 21751231
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Glasgow Early Treatment Arm Favirpiravir (GETAFIX) for adults with early stage COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Hanna CR; Blyth KG; Burley G; Carmichael S; Evans C; Hinsley S; Khadra I; Khoo S; Lewsley LA; Jones RR; Sharma R; Taladriz-Sender A; Thomson EC; Scott JT
    Trials; 2020 Nov; 21(1):935. PubMed ID: 33213530
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Mind the gap: covariate constrained randomisation can protect against substantial power loss in parallel cluster randomised trials.
    Kristunas C; Grayling M; Gray LJ; Hemming K
    BMC Med Res Methodol; 2022 Apr; 22(1):111. PubMed ID: 35413793
    [TBL] [Abstract][Full Text] [Related]  

  • 45. SPIKE-1: A Randomised Phase II/III trial in a community setting, assessing use of camostat in reducing the clinical progression of COVID-19 by blocking SARS-CoV-2 Spike protein-initiated membrane fusion.
    Halford S; Wan S; Dragoni I; Silvester J; Nazarov B; Anthony D; Anthony S; Ladds E; Norrie J; Dhaliwal K;
    Trials; 2021 Aug; 22(1):550. PubMed ID: 34412682
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evaluating tests for cluster-randomized trials with few clusters under generalized linear mixed models with covariate adjustment: A simulation study.
    Qiu H; Cook AJ; Bobb JF
    Stat Med; 2024 Jan; 43(2):201-215. PubMed ID: 37933766
    [TBL] [Abstract][Full Text] [Related]  

  • 47. An investigation into the beneficial effects of high-dose interferon beta 1-a, compared to low-dose interferon beta 1-a (the base therapeutic regimen) in moderate to severe COVID-19: A structured summary of a study protocol for a randomized controlled l trial.
    Alavi Darazam I; Hatami F; Rabiei MM; Pourhoseingholi MA; Moradi O; Shokouhi S; Hajesmaeili MR; Shabani M; Irvani SSN
    Trials; 2020 Oct; 21(1):880. PubMed ID: 33106183
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
    Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
    Trials; 2021 May; 22(1):343. PubMed ID: 34001215
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial.
    Olagunju A; Fowotade A; Olagunoye A; Ojo TO; Adefuye BO; Fagbamigbe AF; Adebiyi AO; Olagunju OI; Ladipo OT; Akinloye A; Adeagbo BA; Onayade A; Bolaji OO; Happi C; Rannard S; Owen A
    Trials; 2021 Jan; 22(1):3. PubMed ID: 33397457
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Baseline characteristics and statistical power in randomized controlled trials: selection, prognostic targeting, or covariate adjustment?
    Roozenbeek B; Maas AI; Lingsma HF; Butcher I; Lu J; Marmarou A; McHugh GS; Weir J; Murray GD; Steyerberg EW;
    Crit Care Med; 2009 Oct; 37(10):2683-90. PubMed ID: 19885979
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Assessment and implication of prognostic imbalance in randomized controlled trials with a binary outcome--a simulation study.
    Chu R; Walter SD; Guyatt G; Devereaux PJ; Walsh M; Thorlund K; Thabane L
    PLoS One; 2012; 7(5):e36677. PubMed ID: 22629322
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
    Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
    Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Estimating the Efficiency Gain of Covariate-Adjusted Analyses in Future Clinical Trials Using External Data.
    Li X; Li S; Luedtke A
    ArXiv; 2021 Apr; ():. PubMed ID: 33948450
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Empirical likelihood inference in randomized clinical trials.
    Zhang B
    Stat Methods Med Res; 2018 Dec; 27(12):3770-3784. PubMed ID: 28679341
    [TBL] [Abstract][Full Text] [Related]  

  • 55. How large are the consequences of covariate imbalance in cluster randomized trials: a simulation study with a continuous outcome and a binary covariate at the cluster level.
    Moerbeek M; van Schie S
    BMC Med Res Methodol; 2016 Jul; 16():79. PubMed ID: 27401771
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
    Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
    Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An evaluation of inverse probability weighting using the propensity score for baseline covariate adjustment in smaller population randomised controlled trials with a continuous outcome.
    Raad H; Cornelius V; Chan S; Williamson E; Cro S
    BMC Med Res Methodol; 2020 Mar; 20(1):70. PubMed ID: 32293286
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Calculating the power of a planned individual participant data meta-analysis of randomised trials to examine a treatment-covariate interaction with a time-to-event outcome.
    Riley RD; Collins GS; Hattle M; Whittle R; Ensor J
    Res Synth Methods; 2023 Sep; 14(5):718-730. PubMed ID: 37386750
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A new nonparametric approach for baseline covariate adjustment for two-group comparative studies.
    Schacht A; Bogaerts K; Bluhmki E; Lesaffre E
    Biometrics; 2008 Dec; 64(4):1110-6. PubMed ID: 18266888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Nebulised surfactant for the treatment of severe COVID-19 in adults (COV-Surf): A structured summary of a study protocol for a randomized controlled trial.
    Dushianthan A; Clark H; Madsen J; Mogg R; Matthews L; Berry L; de la Serna JB; Batchelor J; Brealey D; Hussell T; Porter J; Djukanovic R; Feelisch M; Postle A; Grocott MPW
    Trials; 2020 Dec; 21(1):1014. PubMed ID: 33302976
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.